Targeting the acetylation of Tau at residue 174 or restoring SIRT6 levels could mitigate Tau accumulation and potentially offer therapeutic strategies for Alzheimer’s disease. The gene discussed is SIRT6; the disease is early-onset autosomal dominant Alzheimer disease.